Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward sectors like obesity and cancer, as sales for some of the new treatments ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in ...

Farther Finance Advisors LLC boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 34.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

We recently published a list of 12 Most Shorted Stocks in 2025. In this article, we are going to take a look at where CRISPR ...

Top 10 Stocks to Buy. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Stock price predictions for 2025 are increasingly "meta." No, not the Facebook parent, but rather the idea that investments are increasingly self-referential rather than reliant on outside ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE ...

What is the current share price of CRISPR Therapeutics AG (CRSP)? CRISPR Therapeutics AG's (CRSP) current share price is $42.31. This constitutes a price movement of 11.69% when compared to the share ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

But for our next session, we have a fireside chat with CRISPR Therapeutics. Very excited to have this discussion, and it's my privilege to introduce Sam Kulkarni, CEO of CRISPR. Sam, thank you ...